Fewer than 10% of people who could benefit from GLP-1 drugs such as Wegovy are able to get them, states the World Health Organization as it publishes its initial advice on the medications.
Considering in excess of 1,000,000,000 people worldwide now obese, it is urging broader and more equitable availability to this class of drugs.
Per estimates, over two billion are projected to be obese by 2030 if no action is taken.
"The latest guidance acknowledges that excess weight is a chronic disease that can be addressed with thorough and ongoing support," said WHO director-general Tedros Adhanom Ghebreyesus.
Significant expense, limited production capacity, and supply-chain constraints are key obstacles to widespread access to the jabs that can help people shift significant weight, notes the agency.
Skinny Jab Shortage
Despite the current most optimistic case, the manufacturing of GLP-1 therapies would only suffice for around 100 million people – less than 10% of eligible patients, according to the health organization.
The recommendation urges governments and firms to expand availability, via strategies like licensing agreements.
Exclusive production rights on a key compound – the primary ingredient of the drug Wegovy – is due to expire in a number of nations in 2026.
The Way Obesity Drugs Operate
GLP-1 drugs imitate a natural hormone to slow digestion, curb appetite and increase the sense of being full so people consume fewer calories.
People commonly see weight reduction in the initial weeks of starting on the once-weekly jabs.
Research suggests people may regain a significant portion within a year of discontinuing the treatment, because their normal hunger return.
Being carrying excess weight elevates your risk for experiencing health problems, such as type 2 diabetes, cardiovascular issues, stroke, and certain cancers.
Excess weight impacts individuals in every country and was responsible for over three and a half million fatalities worldwide in 2024, per the health agency.
